Talent Pool executive appointments and promotions in the healthcare industry
Pharmaceutical POOL
Dr. Franck BARRAT Roche Broadens Inflammatory Expertise Franck Barrat, Ph.D., has joined Roche’s inflammation discovery and translational areas (DTA) as a distinguished scientist. Dr. Barrat brings to Roche extensive expertise in the roles that dendritic cells, toll receptor agonists and antagonists, and IL10-secreting regulatory T cells play in human diseases. Before joining Roche, Dr. Barrat was senior research fellow and project leader of the autoimmunity program at Dynavax Technologies. He received a Ph.D. in immunology from the University of Paris, a master’s degree in immunology from the Pasteur Institute, and a master’s degree in pharmacology from the University of Nice. Dr. Olivier BRANDICOURT John YOUNG Pfizer Names Emerging Markets President Global pharmaceutical firm Pfizer has appointed Olivier Brandicourt, M.D., president and general manager of the emerging markets and established products business units. Dr. Brandicourt succeeds David Simmons, who has joined PPD as chairman and CEO. Dr. Brandicourt most recently served as president and general manager of Pfizer’s primary care business unit. He received a medical degree with a subspecialty in infectious diseases and tropical medicine, as well as a master’s degree in biology from Paris University. John Young has been promoted to succeed Dr. Brandicourt as president and general manager of the primary care business unit. Mr. Young was previously regional president of Europe and Canada for the primary care business. Robert CLARK Former Pfizer Executive Joins Novo Nordisk as Regulatory VP Global healthcare company Novo Nordisk has named Robert Clark VP, regulatory affairs. Mr. Clark leads Novo Nordisk’s U.S. regulatory team and maintains relationships with key individuals and agencies outside the company that play a specific role in the U.S. FDA’s review and approval process. Mr. Clark comes to Novo Nordisk from Pfizer, where he was most recently U.S. regulatory strategy head. He received an M.S. in pharmacology from New York Medical College. Dr. Michael HAYDEN Teva Appoints R&D Head Teva Pharmaceutical Industries has appointed Dr. Michael Hayden president of global research and development and chief scientific officer, based in Israel. Dr. Hayden is currently Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and director/senior scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. Dr. Harald REINHART Shionogi Adds VP Shionogi Inc., the U.S. division of Japanese pharmaceutical company Shionogi & Co. Ltd., has announced an addition to its leadership. Harald Reinhart, M.D., has been named senior VP of clinical development and medical affairs. Dr. Reinhart most recently served as a global program head, infectious diseases, transplantation and renal, for Novartis. He received an M.D. at the University of Wurzburg in Germany. Dr. Joseph STAUFFER Ikaria Appoints Medical Chief Ikaria, a critical care company focused on developing and commercializing innovative therapies for critically ill patients, has named Joseph Stauffer, D.O., chief medical officer. Dr. Stauffer was most recently chief medical officer at PharmacoFore. He graduated from the Philadelphia College of Osteopathic Medicine and completed an MBA as part of the TRIUM Global Executive MBA Program, a joint degree granted by NYU Stern School of Business, HEC School of Management in Paris, and the London School of Economics and Political Science. Biotechnology POOL Celina CHANG Jack HARVEY InVivo Adds to Science, Manufacturing Expertise InVivo Therapeutics Holdings has expanded its team as the biotech company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions. Celina Chang has joined InVivo as senior scientist, leading the execution and review of experiments per GMP and GLP regulations and undertaking the analysis of various cultured cells for InVivo’s chronic spinal cord injury therapies. Ms. Chang was previously a scientist at Pervasis Therapeutics. Jack Harvey has been named senior director of manufacturing, leading InVivo’s production of GMP polymer-based biomaterial technologies. Mr. Harvey was most recently director of manufacturing at Pervasis Therapeutics. He received an MPH in health law from Boston University School of Public Health. Aron KNICKERBOCKER FivePrime Names Business Chief Five Prime Therapeutics (FivePrime), a company focused on the discovery and development of biologics for oncology and immunology, has promoted Aron Knickerbocker to senior VP and chief business officer. Mr. Knickerbocker joined FivePrime in September 2009 as VP, business development. He received an MBA from the University of Michigan. Dr. Carol REED Synthetic Biologics Appoints Clinical Affairs VP Synthetic Biologics, a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, has named Carol Reed, M.D., senior VP of clinical and regulatory affairs. Dr. Reed is responsible for the design and implementation of all aspects of clinical development, including clinical trials, as well as leading the company’s regulatory initiatives. Most recently, Dr. Reed served as chief medical officer at Clinical Data Inc. She earned an M.D. from Rush Medical College and an M.S. in biology from the University of Illinois. Dr. Paul RUBIN Xoma Promotes R&D Executive Xoma, a company focused on the discovery and development of therapeutic antibodies, has promoted Paul Rubin, M.D., to senior VP, research and development and chief medical officer, further integrating all research, preclinical, and clinical development activities under Dr. Rubin’s leadership. Dr. Rubin joined Xoma in June 2011 as VP, clinical development and chief medical officer and maintains his responsibilities as Xoma’s chief medical officer. He received an M.D. from Rush Medical College. Robert SIMON Threshold Appoints Regulatory Affairs VP Threshold Pharmaceuticals has appointed Robert Simon senior VP of regulatory affairs, overseeing the biotech company’s regulatory activities related to the development of TH-302, a clinical-stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers. Before joining Threshold, Mr. Simon spent almost a decade at OSI Pharmaceuticals, most recently as an executive VP in roles relating to pharmaceutical development, manufacturing, and technical operations. Biopharmaceutical POOL Cynthia COLLINS GenVec Announces CEO Succession GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has named Cynthia Collins to replace retiring President and CEO Paul Fischer, Ph.D. Ms. Collins previously served as group VP, cellular analysis business, at Beckman Coulter. She has an MBA from the University of Chicago Booth School of Business. Dr. Pamela CONLEY iPierian Appoints Research VP iPierian has appointed Pamela Conley, Ph.D., VP of research. Dr. Conley is responsible for the biopharma company’s emerging drug development pipeline for therapeutics to treat neurodegenerative diseases, as well as the company’s proprietary patient-derived induced pluripotent stem cell (iPSC) platform, which provides insight for novel therapeutic targets or mechanisms of disease. Dr. Conley was most recently VP of research biology at Portola Pharmaceuticals. She received a Ph.D. in biochemistry from the University of California, Berkeley. Dr. Howard DITTRICH Sorbent Therapeutics Names Medical Chief Sorbent Therapeutics, a biopharmaceutical company developing therapies for cardiovascular and renal diseases, has appointed Howard Dittrich, M.D., chief medical officer. A cardiologist by training, Dr. Dittrich is applying his extensive expertise in heart failure to the clinical development of CLP1001, Sorbent’s lead therapeutic compound. Dr. Dittrich was previously chief medical officer of Sequel Pharmaceuticals, a spinout from the acquisition of NovaCardia by Merck. He holds an M.D. from the University of Iowa College of Medicine. William HEIDEN AMAG Pharmaceuticals Shifts Leadership AMAG Pharmaceuticals has appointed William Heiden president and CEO. Mr. Heiden was previously president and CEO of GTC Biotherapeutics. He holds an MBA from Cornell University’s Johnson Graduate School of Management and a MIM from the University of Louvain in Belgium. AMAG Pharmaceuticals is a biopharmaceutical company that manufactures and markets Feraheme in the United States for the treatment of iron deficiency anemia in adult chronic kidney disease patients. Dr. Evan LOH Dennis MOLNAR Paratek Names Executives Paratek Pharmaceuticals has named Evan Loh, M.D., chairman and chief medical officer. Dr. Loh succeeds Dr. Walter Gilbert as chairman; Dr. Gilbert remains vice chairman of the board. Dr. Loh joins Paratek from Pfizer, where he was most recently senior VP, development and strategic operations, worldwide research and development. He received an M.D. from Harvard Medical School. Paratek also has announced the promotion of Dennis Molnar to president and CEO, from VP, corporate development. Mr. Molnar succeeds Thomas Bigger, who resigned as CEO earlier this year. Paratek is a biopharma company engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Dr. Gerald MCMAHON Kolltan Pharmaceuticals Announces Executive Transition Privately held biopharmaceutical company Kolltan Pharmaceuticals has named Gerald McMahon, Ph.D., president and CEO. Dr. McMahon replaces Kolltan Co-Founder Arthur Altschul Jr., who continues as executive chairman. Dr. McMahon comes to Kolltan from MedImmune, the biologics arm of AstraZeneca, where he most recently served as senior VP, R&D oncology. He received a Ph.D. in biochemistry from Rensselaer Polytechnic Institute. Dr. Eric WACHTER Provectus Appoints Technology Chief Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has named Eric Wachter, Ph.D., chief technology officer. Dr. Wachter is focused on leading drug development of both PV-10 and PH-10, as well as the intellectual property protection of Provectus’ investigational therapeutic products. Dr. Wachter has been with Provectus since 2002 and previously served as executive VP-pharmaceuticals. He holds a Ph.D. in chemistry from the University of Wisconsin. Dr. Matthew WIKLER Rib-X Names Development Chief Rib-X Pharmaceuticals has appointed Matthew Wikler, M.D., chief development officer. Dr. Wikler’s duties include assuming a strategic leadership role in implementing the Phase III program for delafloxacin, for treating acute bacterial skin and skin structure infections. Before joining Rib-X, Dr. Wikler served as president and CEO of IASO Pharma. He received an M.D. from Temple University and an M.B.A. from the Wharton School of the University of Pennsylvania. Rib-X is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety, and convenience for the treatment of serious and life-threatening infections. Specialty POOL John BARR Bausch + Lomb Names Surgical Business Head Global eye health company Bausch + Lomb has appointed John Barr global president of the company’s surgical business, overseeing the specialty company’s full suite of ophthalmic surgical products, intraocular lenses, and delivery systems. Mr. Barr was most recently president and CEO of AGA Medical. He received a master’s degree in accounting and economics from the Kellogg School of Management, Northwestern University. David BUCHEN Charles MAYR Sigurdur Oli OLAFSSON Robert STEWART G. Frederick WILKINSON Watson Realigns Management Structure Watson Pharmaceuticals has refined and expanded the responsibilities of its senior executive team in the wake of the specialty pharmaceutical company’s continued global expansion and its announced intention to acquire Actavis. David Buchen has been promoted to chief legal officer – global, from executive VP, general counsel, and secretary. Mr. Buchen retains his secretary position and continues to oversee Watson’s global compliance and internal audit functions. Charles Mayr has been promoted to chief communications officer – global. Mr. Mayr joined Watson as senior VP, corporate affairs, in September 2009. Former Actavis Group CEO Sigurdur Oli Olafsson has been named president of global generics. Mr. Olafsson joined Watson as executive VP, global generics in September 2010. As president, global operations, Robert Stewart assumes additional responsibility for managing Watson’s Anda distribution business. Mr. Stewart has served as executive VP, global operations, since August 2010. G. Frederick Wilkinson has been appointed president, global brands and biosimilars. Mr. Wilkinson has served as Watson’s executive VP, global brands, since September 2009. Moji JAMES Dr. Clarence YOUNG Iroko Strengthens Leadership Roster Specialty therapeutics company Iroko Pharmaceuticals has made two key additions to its management team. Moji James has joined Iroko as general counsel and VP, overseeing the company’s legal and compliance activities. Ms. James was previously global product counsel at Pfizer. She received a Master of Laws from London University. Clarence Young, M.D., has been named chief medical officer, responsible for leading Iroko’s clinical programs for its investigational nonsteroidal anti-inflammatory drugs. Dr. Young joins Iroko from Novartis Pharmaceuticals, where he was VP, targeted therapies and integrated hospital care. He is a graduate of Harvard Medical School. LeRoux JOOSTE Antares Pharma Names Marketing VP Antares Pharma, a specialty pharmaceuticals company focused on self-injection pharmaceutical products and topical gel-based medicines, has named LeRoux Jooste senior VP of pharmaceutical sales and marketing. Mr. Jooste joins Antares from Cephalon, where he was most recently VP commercial assessment and new product planning. Dr. Lawrence OLANOFF Ariel Taps Former Forest President as Chairman Ariel Pharmaceuticals, a private, development-stage specialty pharmaceutical company focused on the development and commercialization of products for major unmet medical needs, has appointed Lawrence Olanoff M.D., Ph.D., chairman. Dr. Olanoff was most recently president and chief operating officer for Forest Laboratories. He earned both an M.D. and a Ph.D. in biomedical engineering from Case Western Reserve University. Rajul PARIKH Amanda WOHLLEBER Tris Pharma Announces Management Addition, Promotion Tris Pharma, a technology-driven specialty pharmaceutical company, has promoted key manufacturing executive Rajul Parikh to VP, operations. Mr. Parikh continues to manage all of the company’s manufacturing, packaging, facilities, and engineering activities. In other moves, Amanda Wohlleber has joined Tris Pharma as VP of scale-up and technical services. Ms. Wohlleber brings more than 20 years of pharmaceutical manufacturing and tech service experience to Tris’ technology and manufacturing teams, including roles in validation, tech service, and quality assurance positions at senior levels at a number of generics firms. She has an MBA from Simmons College. Bob RADIE Egalet Appoints Chief Executive Egalet, a privately held specialty pharmaceutical company focused on developing safe, effective, and abuse-resistant medications, has named Bob Radie president and CEO. Mr. Radie was previously president and CEO of Topaz Pharmaceuticals, which was acquired by Sanofi Pasteur in the fourth quarter of 2011. Thomas SOLOWAY Transcept Appoints Operating Chief Transcept Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in the field of neuroscience, has promoted Thomas Soloway to executive VP and chief operating officer. Mr. oloway joined Transcept as a co-founder in 2002 and previously served as senior VP, operations and chief financial officer. He received an MBA from Georgetown University. Device/Diagnostic POOL Michael DRESNER IntegraGen Appoints National Sales Director IntegraGen, a biotechnology company dedicated to molecular biomarker discovery, has named Michael Dresner national sales director. Mr. Dresner is responsible for IntegraGen’s sales efforts in the United States associated with the ARISk Autism Risk Assessment Test. He was most recently director of client and patient services for Oxford Immunotec. Dr. Alexander (Alex) KUTA Nigel WILLIAMS Lantheus Boosts Regulatory, Quality Expertise Lantheus Medical Imaging, a global company focused on developing, manufacturing, and distributing innovative diagnostic imaging agents, has added two VPs to further strengthen the company’s regulatory and quality leadership. Alexander (Alex) Kuta, Ph.D., has been named VP, global regulatory affairs. Dr. Kuta joins Lantheus with more than 20 years of regulatory affairs and drug development experience with the U.S. FDA, Genzyme, and most recently AMAG Pharmaceuticals, where he was VP, regulatory affairs and quality assurance. Nigel Williams has been appointed VP, quality. Mr. Williams was most recently head of quality for Merck KGaA chemicals operations. Ken MARSHALL Aerocrine Taps Former Ikaria VP to Head U.S. Business Ken Marshall has joined Swedish medical technology firm Aerocrine AB’s U.S. division Aerocrine Inc. as president. Mr. Marshall was previously VP of marketing at Ikaria. He earned an MBA from Houston Baptist University. Aerocrine is focused on the improved management and care of patients with inflammatory airway diseases. Dr. Thomas MUSCI Ariosa Selects Clinical Development Lead Ariosa Diagnostics, a molecular diagnostics company, has appointed Thomas Musci, M.D., VP, clinical development and medical affairs. Dr. Musci was previously director of clinical affairs for predictive health with Novartis Diagnostics. He received an M.D. from Georgetown University School of Medicine. Emerging POOL Dr. Eric HEDRICK Epizyme Names Medical Chief Epizyme, a company focused on the discovery and development of personalized therapeutics for patients with genetically defined cancers based on breakthroughs in the field of epigenetics, has named Eric Hedrick, M.D., chief medical officer. Dr. Hedrick joins Epizyme from Pharmacyclics, where he was most recently VP of oncology development and interim chief medical officer. Agency POOL Rob CRONIN WCG Hires Healthcare Technology Practice Leader WCG, an independent global strategic communications consulting firm, has appointed Rob Cronin practice leader, healthcare technology and transformation. Mr. Cronin joins WCG from Surescripts, where he led corporate communications. Mike DENNELLY evoke interaction Selects New York Lead Full-service healthcare agency evoke interaction has appointed Mike Dennelly managing director of its New York office. Mr. Dennelly was previously executive director, strategy at G2 USA, where he was a founding member of the G2 Health and Wellness practice. Beth GEREN Meredith JOLLAY AbelsonTaylor Announces Two Account Team Promotions Independent healthcare advertising agency AbelsonTaylor has promoted Beth Geren to account executive responsible for a low testosterone treatment product. Since joining AbelsonTaylor in 2010, Ms. Geren has worked on products in the areas of acute coronary syndrome and gastroesophageal reflux disease. In other news, Meredith Jollay has been promoted to senior account executive from account executive. Ms. Jollay is working on a product in the area of oncology. She joined AbelsonTaylor in 2007 and has developed and launched the Anemia Awareness Campaign targeting nurses and oncologists, as well as working on products in the areas of cardiology and ophthalmology. Jeremy GROFF Brian GWALTNEY Christy HALLADAY Janice MOORE Chris PINKHAM George RECINE Serene SMITH Danielle STERN LehmanMillet Unveils Promotions on Both Coasts LehmanMillet, a healthcare marketing communications agency dedicated to serving companies seeking to change the standard of care, has announced a number of promotions at its Boston headquarters and its office in Santa Ana, Calif. In Santa Ana, Jeremy Groff has been promoted to account manager, Brian Gwaltney to senior production artist, and Christy Halladay to senior account manager. In Boston, Janice Moore has been elevated to lead designer, Chris Pinkham to associate creative director, art. George Recine has been promoted to senior copywriter. Serene Smith has been promoted to the position of account supervisor in the Santa Ana office. Danielle Stern has been promoted to account supervisor based in Boston. John HOPPER Spirit Health Partnership Appoints Division President Spirit Health Partnership, a wellness marketing firm focused on creating partnerships with brands, community hospitals, and advocacy groups, has named John Hopper division president. Mr. Hopper leads the consumer and professional integrated marketing efforts of Spirit Health, working with pharmaceutical, consumer goods, and financial companies, as well as nonprofit groups and their marketing agencies. Mr. Hopper most recently founded Power Marketing Partners (PMP). He is a graduate of Oxford University’s executive MBA program. Mark MAGNANI Precision Health Media Appoints Veteran Digital Ad Exec as Advertising VP Precision Health Media, an agency that delivers specific health condition audiences to pharma and consumer brands, has named Mark Magnani VP, Advertising Sales. Mr. Magnani has more than 20 years of experience working with senior-level pharma brand managers in online, print, and out-of-home media. Most recently, he was executive VP client services at Healthy Advice Networks. Jason VERBICK FingerPaint Adds to Creative Team FingerPaint Marketing, a fully integrated marketing and advertising agency, has added Jason Verbick to its creative team. Mr. Verbick is responsible for providing creative direction and writing for various clients and multiple projects in all media. He most recently served as senior copywriter for AbelsonTaylor. Consulting POOL Dr. Florian EICHMANN Dr. Vince GRILLO Richard GOOSEY Graeme JACOMBS Stephen POTTS Kantar Health Announces International Additions Kantar Health, a healthcare-focused global consultancy and marketing insights company, has made a number of appointments to its teams in the United Kingdom, Germany, and the Asia Pacific, Middle East, and Africa (APMEA) region. Florian Eichmann, Ph.D., has joined Kantar as business unit director, treatment value, based in Germany. Dr. Eichmann is responsible for the health outcomes, public health, drug surveillance, clinical research, and medical device/diagnostic groups and a service profile ranging from clinical trial operations to health economics and patient-reported outcomes consultancy. Dr. Eichmann was most recently with Kendle, where he led European health outcomes, registries, and observational activities. He holds a master’s and a doctoral degree in biology with a focus on behavioral sciences, endocrinology, and immunology. Vince Grillo, Ph.D., has been appointed general manager, Singapore and Malaysia. Dr. Grillo joined TNS Healthcare, a legacy Kantar Health company, in 2004 and was most recently general manager, Australia. He received a Ph.D. in chemistry from the University of Queensland in Australia. Richard Goosey has been named senior director of advanced methods for Kantar Health UK. Mr. Goosey joins Kantar Health from Roche UK, where he specialized in business planning and forecasting in support of the oncology HER2 franchise. He received a master’s degree in mathematical techniques of statistics and operational research from London University. Graeme Jacombs has been promoted to deputy managing director, APMEA. Mr. Jacombs is responsible for Australia/New Zealand and India in addition to his current responsibilities for Southeast Asia. He joined TNS Healthcare in 1993 and has had a variety of responsibilities for Kantar, most recently as regional director, Southeast Asia. Stephen Potts has been tapped to lead Kantar’s Global Marketing Insights practice. Mr. Potts also continues in his current role as Kantar Health’s managing director of APMEA. He joined TNS Healthcare in 2002. Kevin ESPINOZA CIS Hires Commercial Consulting Practice Lead Life-sciences consulting firm Compliance Implementation Services (CIS) has named Kevin Espinoza VP, practice leader commercial consulting. Mr. Espinoza oversees consulting services and support to provide clients with tailored solutions to effectively identify and mitigate exposure to risk. Mr. Espinoza most recently served as deputy compliance officer for North America pharma at GlaxoSmithKline. He received an MBA from West Virginia Wesleyan College. Mark REIS Diaceutics Names Marketing VP Diaceutics, an international business consulting and software application firm that advises pharmaceutical companies on the development of personalized medicine, has appointed Mark Reis senior VP of business development and marketing. Mr. Reis was most recently director of marketing and business development for DNA Direct, now a wholly owned subsidiary of Medco Health Solutions. Dr. Graham WALKER IDEA Pharma Strengthens Team Dr. Graham Walker has joined IDEA Pharma’s IDEAtion team, working alongside global product teams to innovate path-to-market options for their Phase II compounds. Dr. Walker joins IDEA from AstraZeneca. CRO POOL K. Gary BARNETTE Camargo Adds VP to Durham Office Camargo Pharmaceutical Services, a drug development service provider specializing in the 505(b)(2) process, has named K. Gary Barnette VP of drug development stationed in the CRO’s Durham, N.C., office. Mr. Barnette was previously VP of clinical research and development strategy at GTx. Patricia BLAND Edward IAN Nitin JAIN Brian MOONEY Theorem Announces U.S., Asia Appointments Full-service CRO Theorem Clinical Research has made a number of additions to its leadership team worldwide. Patricia Bland has joined Theorem as executive director of corporate development, responsible for company proposals, customer contracts and marketing, operational vendor management, investigator feasibility and relations, and business intelligence. Ms. Bland previously served as the managing principal for d&d strategic solutions. Theorem has appointed Edward Ian executive director, clinical development, for the Asia-Pacific region within the company’s Taipei, Taiwan, office. Mr. Ian has more than 25 years of experience, including such roles as VP of the Asia-Pacific region for Pharmaceutical Product Development. He earned an executive MBA from National ChengChi University in Taipei. Nitin Jain has been named VP and general manager for the Asia-Pacific region in the Singapore office. Mr. Jain’s responsibilities include overseeing the Asia-Pacific client portfolio and serving as an executive client contact. Mr. Jain was most recently director of business development in the Asia-Pacific region for Covance. He received an MBA from ACL in London. Brian Mooney has joined Theorem as senior VP of global clinical development. Mr. Mooney was previously senior VP of project services for Pharmaceutical Research Associates International. Christopher GAENZLE Dr. Frederick YOUNG INC Research Strengthens Team INC Research, a therapeutically focused clinical research organization, has appointed Christopher Gaenzle general counsel. Mr. Gaenzle’s duties include providing global leadership for INC Research’s legal resources. Mr. Gaenzle was most recently assistant general counsel at Pfizer. He received a J.D. from Syracuse University. In other moves, Frederick Young, Ph.D., has joined INC Research to lead the company’s infectious diseases therapeutic unit globally as VP, infectious diseases. Dr. Young was previously VP of strategic programs at ICON. He received a doctorate in chemistry from Georgia Institute of Technology and an MBA from Rutgers University. Luis GUTIERREZ Jr. Aptiv Solutions Names Commercial Chief Aptiv Solutions, a biopharmaceutical and medical device development services company specializing in adaptive clinical trial design, simulation, and execution, has named Luis Gutierrez Jr. executive VP and chief commercial officer. Mr. Gutierrez oversees Aptiv’s global business development, proposal development, marketing, and brand management functions. He was most recently with MedAssurant, where he served as the senior VP of pharmaceutical and life-sciences operations. Dr. Kevin JOHNSON Novella Clinical Adds Global Regulatory Head Novella Clinical, a full-service clinical research organization, has appointed Kevin Johnson, Ph.D., global head regulatory affairs, supporting Novella’s global oncology, biopharma, and medical device clients. Dr. Johnson most recently worked as director of regulatory affairs and quality systems for the Wake Forest Institute for Regenerative Medicine. He holds a doctorate in neurobiology from the University of North Carolina School of Medicine and an MBA from the University of North Carolina’s Kenan-Flagler Business School. Bill KLITGAARD Covance Appoints Information Chief Covance, a provider of drug development services, has named Bill Klitgaard corporate senior VP and chief information officer (CIO). Mr. Klitgaard was previously Covance’s corporate senior VP and chief financial officer. He earned an MBA from the MIT Sloan School of Management. Kenneth O’BRIEN WCC Strengthens Regulatory Affairs Team WorldCare Clinical (WCC), an imaging CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, has named Kenneth O’Brien executive director of quality and regulatory affairs. Before joining WCC, Mr. O’Brien was responsible for quality system implementation and regulatory compliance at Parexel International, Perceptive Informatics, Phase Forward, and Domain Pharma. Christopher ORE Comprehensive Clinical Development Adds VP Comprehensive Clinical Development, a strategic clinical research company, has appointed Christopher Ore senior VP and general manager, early phase clinical research. Mr. Ore’s previous roles include VP and general manager of Biovail Contract Research Division and executive director clinical pharmacology, North America, with Covance. Tom PIKE Quintiles Appoints CEO Global biopharmaceutical services company Quintiles has named Tom Pike CEO as part of its long-term succession planning. Company founder Dennis Gillings continues as executive chairman. Mr. Pike brings 30 years of experience to Quintiles, including 22 years at Accenture.. David REYNOLDS BASi Names Discovery Director Drug discovery and development services company BASi (Bioanalytical Systems Inc.) has appointed David Reynolds director of discovery services, overseeing studies and staff of the company’s discovery center at its West Lafayette, Ind., headquarters. Mr. Reynolds joins BASi with more than 25 years of experience. David SIMMONS PPD Selects CEO Global contract research organization Pharmaceutical Product Development (PPD) has named David Simmons chairman and CEO. Mr. Simmons joins PPD from Pfizer, where he served as president and general manager of the emerging markets and established products business units. Medical Education POOL Dr. Allison MULLER Institute for Continuing Healthcare Education Appoints Medical Director The Institute for Continuing Healthcare Education, an independent medical education company, has named Allison Muller, Pharm.D., medical director. Dr. Muller was clinical managing director for the Poison Control Center at the Children’s Hospital of Philadelphia. She is a board-certified toxicologist and holds a doctor of pharmacy from the University of Arkansas. Service POOL Ian AU-YEUNG Raman KHATRI Evalueserve Adds Directors to Life Sciences and Healthcare Unit Evalueserve, a global specialist in knowledge processes, has made two appointments to its senior management team. Ian Au-Yeung has joined Evalueserve as senior director in the US, life sciences and healthcare. Mr. Au-Yeung brings 16 years of sales and consulting experience. Raman Khatri has been named director in the US, life sciences and healthcare. Mr. Khatri has more than 18 years of experience. Sue BARROWCLIFFE Jeff OLIVA Idis Bolsters Leadership Team Idis, a company focused on partnering with pharmaceutical and biotechnology companies to create regulatory compliant, ethical access to medicines, has added two industry veterans to its leadership team. Sue Barrowcliffe has joined Idis as global director of regulatory and medical strategy. Jeff Oliva has been appointed senior VP of global business development. Mr. Oliva was chief marketing and sales officer at i3 Global. Dr. Eric Michael DAVID McKinsey Consultant Joins Organovo Organovo Holdings, a biotechnology company focused on delivering breakthrough 3D bioprinting technology, has appointed Eric Michael David, M.D., J.D., chief strategy officer. Dr. David was most recently associate partner at McKinsey & Company. He received an M.D. from Columbia University College of Physicians and Surgeons and a J.D. from Columbia Law School. Dave ESPENSHADE Y-Prime Selects Sales VP Y-Prime Technologies, a provider of clinical trial management consulting services and software solutions, has named Dave Espenshade VP of sales and marketing. Mr. Espenshade was most recently senior VP, sales and marketing, for ePharmaSolutions. Karen FULMER Trios Founder Joins Bench International Bench International, an executive recruiting and consulting firm, has named Karen Fulmer a senior VP in conjunction with Bench’s acquisition of Trios Search Partners. Ms. Fulmer, former founder and president of Trios, is helping to lead Bench’s business development and recruiting activities.
